<?xml version="1.0" encoding="UTF-8"?>
<p>Arbidol hydrochloride (
 <xref ref-type="fig" rid="jcm-09-02084-f012">Figure 12</xref>) is an indole-based derivative antiviral agent that acts as an influenza virus inhibitor and is clinically approved only in Russia and China. Its mechanism of action consists of binding hemagglutinin (HA), a major glycoprotein that is located on influenza virus surface and blocking the fusion of the viral membrane with the endosome. As SARS-CoV-2 also presents hemagglutinin (HA) on its surface, it was hypothesized that Arbidol could be efficient against SARS-CoV-2 [
 <xref rid="B112-jcm-09-02084" ref-type="bibr">112</xref>,
 <xref rid="B127-jcm-09-02084" ref-type="bibr">127</xref>,
 <xref rid="B128-jcm-09-02084" ref-type="bibr">128</xref>]. At present, Arbidol is subjected to clinical trials both as a single agent and in combination with favipravir [
 <xref rid="B112-jcm-09-02084" ref-type="bibr">112</xref>].
</p>
